Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2801MR)

This product GTTS-WQ2801MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2801MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10218MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ15552MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ14079MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ204MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ1126MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ14795MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ12340MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ14593MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW